Review
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 7, 2016; 22(1): 407-416
Published online Jan 7, 2016. doi: 10.3748/wjg.v22.i1.407
Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review
Kichang Han, Jin Hyoung Kim, Gi-Young Ko, Dong Il Gwon, Kyu-Bo Sung
Kichang Han, Jin Hyoung Kim, Gi-Young Ko, Dong Il Gwon, Kyu-Bo Sung, Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Seoul 388-1, South Korea
Author contributions: Kim JH designed the study; Ko GY outlined the draft and supervised the project; Gwon DI and Sung KB searched the reference materials; and Han K wrote the manuscript.
Conflict-of-interest statement: The authors do not have any conflicts to report.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Jin Hyoung Kim, MD, Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, 388-1, Poongnap-2dong, Songpa-gu, Seoul 388-1, South Korea. m1fenew@daum.net
Telephone: +82-2-30104384 Fax: +82-2-4760090
Received: June 26, 2015
Peer-review started: June 27, 2015
First decision: September 11, 2015
Revised: October 15, 2015
Accepted: November 24, 2015
Article in press: November 24, 2015
Published online: January 7, 2016
Core Tip

Core tip: Hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is associated with a grave prognosis if left untreated. Sorafenib is the only treatment modality recommended for treating HCC patients with PVTT according to most international HCC treatment guidelines. However, the survival benefits observed following systemic sorafenib treatment are only marginal. Under these circumstances, the need for better treatment options remains unfulfilled. In this comprehensive review, various treatment options are presented-including transarterial chemoembolization, transarterial radioembolization, hepatic arterial infusion, chemotherapy, and radiotherapy-and their outcomes, along with combination strategies.